Cantor Fitzgerald’s AbbVie ABBV Stock Holding History

Cantor Fitzgerald’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,180	Closed	-$325K	–	257
2023 Q3	$325K	Buy	+2,180	New	+$320K	0.01%	386
2022 Q4	–	Sell	-2,127	Closed	-$285K	–	712
2022 Q3	$285K	Buy	2,127 +27	+1%	+$3.87K	0.01%	571
2022 Q2	$322K	Buy	+2,100	New	+$321K	0.01%	597

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Cantor Fitzgerald's ABBV Position: Q4 2023 in Review

Cantor Fitzgerald sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 2,180 shares — an estimated $325K sold.

Cantor Fitzgerald first reported a position in ABBV in Q2 2022 and held it in 3 quarters. The position peaked at $325K in Q3 2023. 3,323 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

Cantor Fitzgerald reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
Cantor Fitzgerald sold 2,180 AbbVie shares in Q4 2023, an estimated $325K.
Cantor Fitzgerald first reported a position in AbbVie in Q2 2022 and held it in 3 quarters.
Cantor Fitzgerald's AbbVie position peaked at $325K in Q3 2023.
3,323 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.